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Article: Physicians and patients measure different dimension on assessment for gastroesophageal reflux dis-
ease-related symptoms
Lopez-Alvarenga JC, Sobrino-Cossio S, Fass R, Vargas-Romero JA
(J Neurogastroenterol Motil 2011;17:381-386)
Gastroesophageal reflux disease (GERD) is one of the most 
prevalent gastrointestinal (GI) disorders in Western countries. It 
is estimated that for an adult population, daily symptoms occur in 
approximately 5% to 10% of population and once a week symp-
toms in 8% to 29%.
1-3 Moreover, the prevalence of GERD has 
increased tenfold in the years from 1970 to 1995.
4,5
Diagnostics modalities for GERD include the medical his-
tory, symptom questionnaires, upper GI endoscopy, 24 hour 
esophageal pH-monitoring and the proton pump inhibitor (PPI) 
test. During the last decade it has been recognized that majority 
of patients with reflux disease do not have endoscopically visible 
mucosal lesions.
6 In the past many physicians and scientists were 
skeptical about the symptom assessment after treatment and rath-
er tended to analyze data from endoscopy, however, perspective 
the therapeutic effect of a drug on the symptoms is most im-
portant from patient's perspective. Upper endoscopy is an ex-
pensive and invasive examination, and therefore it is difficult to 
consider this method as useful in assessment of treatment effects 
of patients with GERD. It seems that the best methods to meas-
ure the therapeutic efficacy are symptom assessment and symp-
tom improvement. Reliable and valid evaluation methods are 
most needed for clinical trials of GERD therapies. Although, ac-
cording to many researchers, most recent assessment scales are 
insufficient for a full and reliable assessment of the different types 
of GERD.
For the quantitative evaluation of symptoms of the disease 
and the influence on quality of life, different types of question-
naires are used as assessment tools to evaluate the treatment 
effect. They are used in determining diagnosis of GERD, and al-
so in evaluation of different types of treatment. A number of 
symptom scales and questionnaires have been used in clinical tri-
als, but not all of them have been fully validated. Furthermore, 
these scales should be objective, relevant to clinical practice, prac-
tical for use and economical with low price.
7 During designing 
symptom scales for GERD evaluation, it is important to re-
member about the whole spectrum of GERD symptoms, includ-Anita Gasiorowska
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ing typical and atypical ones. The multidimensional symptom 
scale should cover all types of symptoms. Additionally, some-
times it is difficult to assess symptoms reliably at a single time 
point, because GERD symptoms may occur episodically and may 
be triggered by food, stress and physical exercise. Sometimes 
presence of typical and atypical symptoms of GERD, causes sig-
nificant impact on daily activities and reduction of physical 
strength. Additionally, scales should be available in different lan-
guages for use in international studies and for multinational 
comparison.
During analysis of GERD symptoms, it is essential not to 
forget about possibility of discrepancies between documented 
gastroesophageal reflux, esophageal injury and the presence of 
symptoms. As it has been discovered, relationship between symp-
toms and the presence and severity of esophagitis is poor.
8 
Moreover in many patients with extraesophageal symptoms such 
as cough and hoarseness typical symptoms may be absent.
9,10
In this issue of the Journal, Lopez-Alvarenga et al
11 eval-
uated the existence of correlation between physician and patient 
measurement of symptoms in GERD. Authors started to use ex-
pression clinimetrics, which are measurement of clinical symp-
toms and procedure that help in diagnosis, characterization or 
evaluation of clinical entities. Besides, they pointed out that, in or-
der to characterize treatment efficacy, the clinical endpoints have 
to be properly evaluated. That is why, patients were using reflux 
questionnaire - ReQuest, symptom assessment tool developed for 
the use in GERD patients which validity, reliability and high re-
sponsiveness have been documented in patients with GERD.
12 
Whereas, physicians used a questionnaire which consisted of 18 
questions on classical symptoms of GERD, dyspepsia and extra-
esophageal manifestations. In the past the authors demonstrated 
that this structured interview had enough sensitivity to detect 
group differences in symptom severity or its changes by PPI 
treatment.
13,14
The authors revealed that symptoms severity of GERD as-
sessed by physicians did not correlate with symptoms severity as-
sessed by patients. However, both tools recorded improvement of 
patient’s symptoms after 4 weeks of treatment by pantoprazole. In 
previous reports, there were many suggestions regarding who 
should assess the symptoms in GERD patients such as - inves-
tigator, nurse, psychologist or patients. Some authors believed 
that the patients might not be able to recognize or identify symp-
toms using the same terminology as nurses or physicians. Thus, 
self-assessment scales need to be easily understood by patients 
aided with “word pictures” to describe symptoms rather than 
medical terms.
15 Self-assessment of symptoms is the best choice 
because it is the patients neither the investigator nor the nurse 
who experiences the symptoms. This form of symptom assess-
ment is usually associated with lower cost, and considering the 
high prevalence of GERD, it may have significant economic 
impact. Moreover some authors highlighted that physicians 
tended to underscore the severity of symptoms.
16 Current re-
search studies indicated that even when physicians and patients 
were evaluating the same disease, the dimensions measured were 
not the same. The principal symptoms of GERD are heartburn 
and regurgitation which have been discovered many years ago 
and heartburn, when it is the predominant symptom, may be the 
basis for the diagnosis of reflux disease. Many patients with 
GERD report multiple symptoms referable to the GI tract, in-
cluding those that may be attributable to functional dyspepsia and 
irritable bowel syndrome, therefore assessment method is very 
complex.
17 For example, a recent study reported that a significant 
proportion of patients with GERD symptoms also experienced 
symptoms compatible with the diagnosis of the irritable bowel 
syndrome and functional dyspepsia.
18 Additionally, co-morbid 
psychological distress was reported more commonly in patients 
with GERD symptoms. Population-based studies have identified 
p syc hia tric  d is ea se a s a  risk  fa cto r fo r G E R D  sym p tom s .
19,20 
Recently Nojkov et al
21 showed that co-morbid psychological dis-
tress was independently associated with more severe GERD 
symptoms at baseline and more residual symptoms after PPI 
therapy. These data suggest that co-morbid IBS or psychological 
distress may influence the assessment of GERD symptoms by 
patients.
Rigorous development of interview methods or question-
naires requires identifying accurate descriptive wording for 
symptoms. Traditionally, experts define symptoms with limited 
input from patients regarding the content and clarity of defini-
tions. Generally, heartburn is a term which is poorly identified by 
patients and often misinterpreted. That is why patient responses 
are not consistent with the definition of heartburn used by phy-
sician.
22
Additionally in this study, authors found out that the medical 
specialty of the physician influenced the perception of the symp-
tom severity of GERD. It happens probably, because patients 
with different predominant symptoms are treated by doctors of 
different specialties. Most of the patients seen by primary care 
physicians for GERD have wide spectrum of symptoms from 
classical heartburn symptoms through abdominal pain to respira-
tory symptoms. On the other hand, patients consulted from the Patient or Physician
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primary care physicians, usually go to the surgeon if symptoms 
persist.
Symptoms are an important part of GERD treatment out-
come and may be included as part of a disease specific instru-
ment. Work of Lopez-Alvarenga and colleagues
11 suggests that 
questionnaires filled by patients and physician driven tools do not 
correlate because they measure diverse orthogonal dimensions 
and structured approach to assess treatment response may be the 
preferred diagnostic method. However, the question asked by re-
searchers during the discussion: who should perform the meas-
urement - physician or patient - still remains without a definite 
answer.
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